Is Becton, Dickinson and Company (BDX) Undervalued?
The traditional Graham Number cannot be calculated for Becton, Dickinson and Company (BDX) due to missing data. Consider using DCF or other valuation methods for a complete picture.
Analysis updated March 6, 2026
BDX Key Valuation Metrics
| Metric | Value | Signal |
|---|---|---|
| Current Price | $168.23 | — |
| Graham Number | N/A | — |
| P/E Ratio | N/A | Unprofitable |
| P/B Ratio | N/A | — |
| DCF Fair Value | N/A | — |
| Dividend Yield | 1.95% | — Moderate |
| 52-Week Range | $127.59 – $187.35 | Mid-range |
| Market Cap | N/A | Micro Cap |
| Sector | Healthcare | — |
How We Calculated BDX's Graham Number
The Graham Number, developed by Benjamin Graham (the father of value investing), estimates a stock's maximum fair price based on its earnings and book value.
Graham Number = √(22.5 × EPS × BVPS)
For Becton, Dickinson and Company (BDX):
- Earnings Per Share (EPS): N/A
- Book Value Per Share (BVPS): N/A
BDX Dividend Profile
Becton, Dickinson and Company currently pays a quarterly dividend of $0.82 per share, yielding 1.95% at the current price.
| Annual Dividend | $3.28 |
| Dividend Yield | 1.95% |
| Payout Ratio | N/A |
| Consecutive Years Paid | 0+ years |
| 5-Year Dividend Growth | N/A |
| Payment Frequency | Quarterly |
👑 Becton, Dickinson and Company is a Dividend Aristocrat — it has increased its dividend for 25+ consecutive years.
BDX Value Score: 0/10
Our proprietary value score rates Becton, Dickinson and Company a 0 out of 10, placing it in the “Overvalued / Caution” category for value investors.
Score Components
Graham Number not available
P/E not available
P/B not available
DCF value not available
Modest dividend yield
Weak balance sheet metrics
Score methodology: How We Score Stocks
Stocks Similar to BDX
These Healthcare stocks have similar valuation profiles to Becton, Dickinson and Company:
Frequently Asked Questions About BDX
Is BDX undervalued right now?
Based on Graham Number analysis, BDX does not appear significantly undervalued as of March 6, 2026. The Graham Number of $N/A compared to the current price of $168.23 indicates a N/A% difference.
What is Becton, Dickinson and Company's intrinsic value?
Using our DCF model, Becton, Dickinson and Company's estimated intrinsic value is $N/A per share. The Graham Number suggests a fair value of $N/A.
What is the Graham Number for BDX?
The Graham Number for BDX is $N/A, calculated using EPS of $N/A and Book Value Per Share of $N/A. The formula is sqrt(22.5 x EPS x BVPS).
Does BDX pay a dividend?
Yes, BDX pays dividends with a yield of 1.95%. The annual dividend is $3.28 per share. It has paid dividends for 0+ consecutive years.
Is BDX a good buy right now?
Our value score rates BDX a 0/10. The stock is in the "Overvalued / Caution" category. However, this is analysis — not financial advice. Consider your own risk tolerance, portfolio allocation, and investment timeline before making any decisions.
Start Analyzing BDX Today
Ready to invest in Becton, Dickinson and Company? Open a free brokerage account and start trading BDX with $0 commissions.
We may earn a commission when you open an account through our links. This does not affect our analysis or ratings.
Learn More About Value Investing
Tools
- Graham Number Calculator — Calculate the Graham Number for any stock
- DCF Calculator — Run your own discounted cash flow analysis
- Stock Screener — Filter stocks by value metrics
Related Articles
About Becton, Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and ...
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial advice, a recommendation, or a solicitation to buy or sell any security. Past performance does not guarantee future results. Always do your own research and consult a licensed financial advisor before making investment decisions. Data sourced from Financial Modeling Prep API and may be delayed. Last updated: March 6, 2026.